Update shared on 24 Nov 2025
Fair value Decreased 11%Evonik Industries’ analyst price target has been reduced from approximately €18.12 to €16.14. Analysts point to a more cautious outlook on the company’s prospects, citing a series of sector downgrades and lowered revenue growth expectations.
Analyst Commentary
Analyst sentiment on Evonik Industries has become more mixed in recent weeks. Price target revisions reflect changing expectations around valuation, sector dynamics, and the company's future growth trajectory.
Bullish Takeaways- Some bullish analysts continue to support a higher valuation, citing upside potential and maintaining positive ratings despite the sector's recent challenges.
- There remains conviction among these analysts that Evonik’s underlying fundamentals and earnings power present longer-term growth opportunities.
- Supporters see potential for recovery if structural issues within the sector are addressed and market conditions improve.
- Price targets from this group, while reduced, still remain above the current share price. This suggests room for appreciation if company execution improves.
- Bearish analysts point to ongoing cyclical and structural pressures that pose downside risks to earnings estimates and growth.
- Lowered price targets across the board highlight caution regarding the pace of revenue growth and margin recovery in the near term.
- There is increased preference in the sector for less diversified chemicals names, with more focus on industrial gases and specialty ingredients businesses.
- Some have moved to more neutral or hold ratings, reflecting uncertainty around Evonik's ability to outperform peers in a challenging market environment.
What's in the News
- Evonik Industries issued new earnings guidance, projecting revenue of approximately €3.4 billion for the third quarter of 2025, compared to €3.8 billion for the same period in 2024 (Corporate Guidance).
- Evonik has announced a strategic collaboration with Ethris to develop and market an innovative lipid nanoparticle platform for nucleic acid delivery. This collaboration aims to enhance capabilities for targeted therapies and vaccines (Strategic Alliances).
Valuation Changes
- Consensus Analyst Price Target: Lowered from approximately €18.12 to €16.14, reflecting a more cautious outlook.
- Discount Rate: Increased from 5.08% to 6.38%, indicating higher perceived risk or required return.
- Revenue Growth: Marginally decreased from 1.57% to 1.47%, suggesting slightly weaker sales expectations.
- Net Profit Margin: Increased from 4.21% to 4.28%, pointing to a modest improvement in projected profitability.
- Future P/E: Reduced from 14.99x to 13.55x, signaling softer earnings expectations or lower valuation multiples.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.